Company profile for GenFleet Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Founded in 2017, GenFleet Therapeutics Inc. is a China-based R&D biotech company pursuing innovative therapeutic molecules–small and large. We focus on developing cutting-edge products, which potentially serve as globe-wise front runners among "first-in-class" therapeutics with novel mechanism of actions. To achieve this goal, we are leveraging China's local advantages with a global prospective for new drug research and deve...
Founded in 2017, GenFleet Therapeutics Inc. is a China-based R&D biotech company pursuing innovative therapeutic molecules–small and large. We focus on developing cutting-edge products, which potentially serve as globe-wise front runners among "first-in-class" therapeutics with novel mechanism of actions. To achieve this goal, we are leveraging China's local advantages with a global prospective for new drug research and development...

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
China
Address
Address
1206 Zhangjiang Rd., Bldg A, Pudong District, Shanghai
Telephone
Telephone
021-6882 1388
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251019413455/en/Verastem-Oncology-Announces-Updated-Data-from-Partner-GenFleet-Therapeutics-Phase-12-Monotherapy-Study-in-China-of-GFH375-VS-7375-in-Advanced-KRAS-G12D-Mutant-Pancreatic-Ductal-Adenocarcinoma

BUSINESSWIRE
19 Oct 2025

https://www.businesswire.com/news/home/20250602539645/en/Verastem-Oncology-Announces-Updated-Data-from-Partner-GenFleet-Therapeutics-Phase-1-Study-in-China-of-GFH375-VS-7375-an-Oral-KRAS-G12D-ONOFF-Inhibitor

BUSINESSWIRE
02 Jun 2025

https://www.businesswire.com/news/home/20250423863470/en/Verastem-Oncology-Announces-U.S.-IND-Clearance-of-VS-7375-Oral-KRAS-G12D-ONOFF-Inhibitor-Enabling-Phase-12a-Trial-in-Advanced-Solid-Tumors

BUSINESSWIRE
23 Apr 2025

https://www.businesswire.com/news/home/20250114621288/en

BUSINESSWIRE
14 Jan 2025

https://www.expresspharma.in/dupert-offers-new-hope-for-advanced-nsclc-patients-as-chinas-first-kras-g12c-inhibitor-globaldata/

EXPRESSPHARMA
09 Sep 2024

https://www.prnewswire.com/news-releases/genfleet-announces-the-first-approval-of-a-kras-g12c-inhibitor-in-china-for-treatment-of-advanced-non-small-cell-lung-cancer-patients-harboring-kras-g12c-mutation-302229438.html

PR NEWSWIRE
23 Aug 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty